- Home
- GNLX vs FATE Comparison
GNLX vs FATE Comparison
Compare GNLX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- FATE
- Stock Information
- Founded
- GNLX 2001
- FATE 2007
- Country
- GNLX United States
- FATE United States
- Employees
- GNLX N/A
- FATE N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- FATE Health Care
- Exchange
- GNLX Nasdaq
- FATE Nasdaq
- Market Cap
- GNLX 184.4M
- FATE 152.4M
- IPO Year
- GNLX 2023
- FATE 2013
- Fundamental
- Price
- GNLX $2.96
- FATE $1.04
- Analyst Decision
- GNLX Strong Buy
- FATE Hold
- Analyst Count
- GNLX 4
- FATE 8
- Target Price
- GNLX $17.75
- FATE $5.43
- AVG Volume (30 Days)
- GNLX 138.3K
- FATE 2.1M
- Earning Date
- GNLX 05-06-2025
- FATE 05-20-2025
- Dividend Yield
- GNLX N/A
- FATE N/A
- EPS Growth
- GNLX N/A
- FATE N/A
- EPS
- GNLX N/A
- FATE N/A
- Revenue
- GNLX N/A
- FATE $13,631,000.00
- Revenue This Year
- GNLX N/A
- FATE N/A
- Revenue Next Year
- GNLX N/A
- FATE N/A
- P/E Ratio
- GNLX N/A
- FATE N/A
- Revenue Growth
- GNLX N/A
- FATE N/A
- 52 Week Low
- GNLX $1.60
- FATE $0.66
- 52 Week High
- GNLX $5.89
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- GNLX 54.28
- FATE 46.67
- Support Level
- GNLX $2.26
- FATE $0.91
- Resistance Level
- GNLX $3.06
- FATE $1.34
- Average True Range (ATR)
- GNLX 0.31
- FATE 0.13
- MACD
- GNLX 0.04
- FATE -0.03
- Stochastic Oscillator
- GNLX 78.42
- FATE 22.41
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.